Key Highlights
- Precision Optics (NASDAQ:POCI) grew fiscal first-quarter Revenue 22.0% to USD 8,152,083, lifted gross Margin to 22.5% from 14.2% and cut its net loss to USD 474,854.
- IRIDEX (NASDAQ:IRIX) saw third-quarter revenue fall 18.6% to USD 10.2 million, yet gross margin rose to 42.4% from 32.1% and the net loss narrowed to USD 1.4 million.
- Insight Molecular Diagnostics (NASDAQ:IMDX) must send a complete response to the FDA by January 21, 2027 on its GraftAssureDx De Novo request, with USD 11.0 million of cash at quarter end.
- Modular Medical (NASDAQ:MODD) lost USD 7.1 million in its fiscal second quarter, holds USD 5.1 million of cash and flags substantial doubt about its ability to continue as a going concern.
Precision Optics (NASDAQ:POCI): Growth With Wider Margins
Precision Optics (NASDAQ:POCI) designs and makes ultra-high precision endoscopes and very small lenses and assemblies for minimally invasive surgery, along with defense and aerospace work. Its fiscal first-quarter revenue rose 22.0% to USD 8,152,083, led by Systems Manufacturing at USD 5,785,153, up 18.9%, and a MicroOptics Lab line that rose 204.7% on new defense orders. Gross margin widened to 22.5% from 14.2%, which the company credits to better yields, higher royalties and more Ross Optical and MicroOptics Lab revenue. Net loss narrowed to USD 474,854 from USD 1,637,030, a calculated improvement of about 71%. Operating Activities used USD 672,145 of cash, and cash and cash equivalents were USD 8,966,889 at September 30, 2026. A lender replaced the Debt service coverage test with a USD 2.0 million minimum Liquidity covenant, which the company met, and no revolver borrowings were outstanding at quarter end. Shares outstanding were 10,994,430 as of November 12, 2026, according to the Quarterly Report filed on November 16. Management highlights that the rebuilt margin structure and higher Royalty income are the main drivers behind the narrower loss, which readers can track in coming quarters.
IRIDEX (NASDAQ:IRIX): Margin Up, Revenue Down 18.6%
IRIDEX (NASDAQ:IRIX) makes laser systems and delivery devices for eye surgeons, with the Cyclo G6 glaucoma system as its growth product. Third-quarter revenue fell 18.6% to USD 10.2 million from USD 12.5 million, which the company attributes to macroeconomic conditions and customer purchases pulled forward into an earlier period of fiscal 2026. Retina sales fell 23.6%. Gross margin still rose to 42.4% from 32.1%, helped by cost reduction work and a move to lower cost contract manufacturers, partly offset by higher product costs tied to tariffs. The net loss narrowed to USD 1.4 million, or USD 0.08 per share, from USD 1.6 million. Cash and cash equivalents were USD 3.7 million at October 3, 2026, against USD 6.0 million at the start of the fiscal year, and nine-month operating activities used USD 2.1 million. Calculated from those figures, the balance covers about 16 months at that pace. The cover page lists 17,807,470 shares outstanding as of November 11, 2026. Higher product costs from tariffs remain a stated headwind, and the filing ties future margin direction to cost reduction work with contract manufacturers.
Insight Molecular Diagnostics (NASDAQ:IMDX): FDA Deadline of January 21, 2027
Insight Molecular Diagnostics (NASDAQ:IMDX) develops molecular test kits that let hospitals and laboratories run transplant rejection testing in-house, built on a digital PCR instrument from its partner Bio-Rad. It submitted a De Novo request for its GraftAssureDx kitted test on March 25, 2026, and on July 25 the FDA sent a letter citing deficiencies, mainly in clinical validation study design and analysis. The request is on hold and is treated as withdrawn if a complete response is not received by January 21, 2027. Third-quarter revenue was USD 559,000 against USD 260,000, with one laboratory services customer contributing about USD 538,000. The net loss narrowed to USD 3.6 million from USD 10.9 million, helped by a USD 4.1 million gain on contingent consideration rather than by operations. Cash and cash equivalents were USD 11.0 million at September 30, 2026, after nine-month operating cash use of USD 23.3 million, and management did not conclude that substantial doubt exists. Shares outstanding were 32,757,434 on November 9, 2026. The filing places the response timeline squarely on the company, so progress on the study analysis is the item to follow before the January date.
Modular Medical (NASDAQ:MODD): Going Concern Doubt Before Revenue
Modular Medical (NASDAQ:MODD) is a commercial-stage medical device Business developing MODD1, a two-part patch insulin pump that received FDA clearance in September 2024. For the fiscal second quarter ended September 30, 2026, the net loss was USD 7.1 million, or USD 0.90 per share, against USD 7.8 million, or USD 4.21 per share, with the per-share change reflecting a 1-for-30 reverse split in March 2026. Selling, general and administrative expense rose 43.8% to USD 3.2 million on outsourced sales and Marketing consulting, while Research and Development fell 29.8% to USD 3.9 million. Cash was USD 5.1 million after USD 12.3 million used in operations over six months and USD 11.2 million raised in financing. The filing says the company has no revenue to cover operating costs and flags substantial doubt about its ability to continue as a going concern. It also disclosed a material weakness tied to accounting for a commercialization services contract. Shares outstanding were 9,736,909 as of November 12, 2026. The absence of revenue means the funding path, not sales, drives the near-term picture, and the material weakness adds a reporting-control item to the risk list.
Where Things Stand
The split is between growth, shrinking sales and regulatory or funding hurdles. Precision Optics (NASDAQ:POCI) grew revenue 22.0% and cut its loss by about 71% on a calculated basis. IRIDEX (NASDAQ:IRIX) lifted gross margin to 42.4% even as revenue fell 18.6%. Insight Molecular Diagnostics (NASDAQ:IMDX) must answer the FDA by January 21, 2027. Modular Medical (NASDAQ:MODD) carries going concern doubt on USD 5.1 million of cash. Next markers are margin durability and the liquidity covenant at the first company, hospital Capital spending at the second, the complete FDA response at the third and the next capital raise at the fourth. None of this is a forecast or a guarantee. Watch the quarterly filings from each for changes in cash and covenants.






Please wait processing your request...